Markers of inflammatory activation: Upregulation of complement receptors CR1 and CR3 on synovial fluid neutrophils from patients with inflammatory joint disease

Regional Immunology Laboratory, Royal Victoria Hospital, Queen's University of Belfast, Northern Ireland.
Clinical Immunology and Immunopathology 11/1992; 65(2):135-42. DOI: 10.1016/0090-1229(92)90216-B
Source: PubMed


Expression of the C3 receptors CR1 and CR3 was investigated on neutrophils from paired peripheral blood and synovial fluid samples from 34 patients with inflammatory joint disease (21 patients with rheumatoid arthritis (RA) and 13 patients with other articular diseases (OAD)). Using monoclonal antibodies (anti-CD35, anti-CD11b) and immunofluorescence flow cytometric analyses the percentages of positively labeled cells and the relative fluorescence intensities (as a measure of receptor number) were determined. CR1 and CR3 were found to be present on the majority (> 85%) of circulating neutrophils from normal subjects, RA and OAD patients, and on synovial fluid neutrophils from both patient groups. A strong correlation between neutrophil CR1 and CR3 expression was observed in peripheral blood samples from normal subjects (r = 0.81; P = 0.001), RA (r = 0.79; P = 0.001), and OAD patients (r = 0.83; P = 0.001); in each case the levels of CR3 expression were approximately twice those recorded for CR1. Both CR1 and CR3 expression was upregulated on synovial fluid neutrophils compared with that observed on the corresponding peripheral blood cells. Mean percentage increases observed were: RA patients: CR1, 16.5% (P < 0.001) and CR3, 28.7% (P < 0.001); and OAD patients: CR1, 4.1% and CR3, 26.9% (P = 0.001). Correlation of serum and synovial fluid IL-6, IL-8, and immune complex levels with neutrophil CR1 and CR3 expression failed to demonstrate any significant relationship between the concentrations of these soluble factors and receptor expression. Upregulation of CR1 and CR3 receptors, reflecting neutrophil activation within the inflamed joint, is a consistent finding in patients with inflammatory arthropathies.

8 Reads
  • Source
    • "Humic substances also possess antioxidant activities (Aeschbacher et al., 2012; Kučerík et al., 2008; Vašková et al., 2011) and inhibit the expression of complement receptor one and three in lipopolysaccharide-induced human umbilical vein endothelial cells through the inhibition of nuclear factor kappa B activation (Gau et al., 2000). These surface molecules play an important role during inflammation by assisting the cells to adhere to the walls of blood vessels in the vicinity of inflammatory reactions as in the case of patients suffering from autoimmune diseases (Crockard et al., 1992). The previously mentioned results were confirmed with a potassium humate product derived from brown coal (Joone and van Rensburg, 2004). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Humic substances are effective in the suppression of delayed type hypersensitivity, rat paw oedema, a graft-versus-host reaction and contact hypersensitivity in rats. They reduce the C-reactive protein levels of patients suffering from osteoarthritis of the knee and the wheel and flare reaction of patients suffering from hay fever. They have also been described as cardioprotective and pro-angiogenic. Toxicity studies have indicated that potassium humate is safe in humans up to a daily dosage of 1 g/kg, whereas fulvic acid is safe in humans up to a daily dosage of 1.8 g per adult. The antiinflammatory action of potassium humate can be contributed to the inhibition of the release of inflammatory-related cytokines, an adhesion molecule, oxidants and components of the complement system. Copyright © 2015 John Wiley & Sons, Ltd. Copyright © 2015 John Wiley & Sons, Ltd.
    Phytotherapy Research 03/2015; 29(6). DOI:10.1002/ptr.5319 · 2.66 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Diss. -- Helsingin yliopisto.

Show more

Similar Publications